Notably, NE-005 induced drastic degradation of CK1α, which is involved in the anti-5q MDS activity of lenalidomide7, at 100-fold lower concentrations than those of lenalidomide (Fig. 1e, f). Here, CSNK1A1 is linked to myelodysplastic syndrome.